Last reviewed · How we verify
NCT07079423
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
Phase 2 trial testing Teclistamab (Tec) in AL Amyloidosis in 35 participants. Currently enrolling.
31 January 2027
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 35 |
| Start date | 28 June 2025 |
| Primary completion | 31 January 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Teclistamab (Tec) — full drug profile →
Conditions studied
- AL Amyloidosis — all drugs for AL Amyloidosis →
Sponsor
Peking Union Medical College Hospital
Who can join
18 and older, any sex, with AL Amyloidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase II study in patients with newly diagnosed Mayo stage IIIB immunoglobulin light-chain (AL) Amyloidosis to evaluate the efficacy and safety of teclistamab
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07079423
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Teclistamab (Tec)
Trials testing the same drug.
- NCT06935162 — Teclistamab in Previously Treated AL Amyloidosis · Phase 2 · recruiting
- NCT06699394 — Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis · NA · recruiting
- NCT05695508 — GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 · Phase 2 · recruiting
Other recruiting trials for AL Amyloidosis
Currently open trials in the same condition.
- NCT07448935 — One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS · recruiting
- NCT07448779 — Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment · recruiting
- NCT06935162 — Teclistamab in Previously Treated AL Amyloidosis · Phase 2 · recruiting
- NCT06699394 — Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis · NA · recruiting
- NCT06569147 — Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis · Phase 1, PHASE2 · recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07079423 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 23 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07079423.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing